系统性风湿性疾病是以自身免疫细胞功能紊乱继而产生多系统多器官损害的一类自身免疫性疾病.传统免疫抑制剂在系统性风湿性疾病治疗中占有重要地位,而临床中仍有相当数量的难治性系统性风湿性疾病对传统免疫抑制剂治疗反应不佳,需要探索新的治疗手段.嵌合抗原受体 T 细胞(chimeric antigen receptor T cell therapy,CAR-T)免疫疗法起始于恶性血液系统疾病治疗,并展现出了良好的疗效,近期CAR-T免疫疗法在难治性系统性红斑狼疮中取得了显著疗效,从而为系统性风湿性疾病的治疗带来新的希望.本文就近年来CAR-T免疫疗法在系统性风湿性疾病临床研究进展进行总结,旨在增强临床医师对CAR-T免疫疗法的认知并推动CAR-T免疫疗法在系统性风湿性疾病中进一步开展.
Advances in clinical research of CAR-T immunotherapy for systemic rheumatic diseases
Systemic rheumatic disease is a kind of autoimmune disease which is caused by the dys-function of autoimmune cells and the damage of multiple systems and organs.Traditional immuno-suppressants play an important role in the treat-ment of systemic rheumatic diseases,but there are still a considerable number of refractory systemic rheumatic diseases that do not respond well to tra-ditional immunosuppressant therapy,and new ther-apeutic methods need to be explored.Chimeric an-tigen receptor T cell therapy(CAR-T)immunothera-py was initially used for the treatment of malig-nant hematological diseases and has shown good efficacy.Recently,CAR-T immunotherapy has also achieved remarkable efficacy in refractory systemic lupus erythematosus.It brings new hope for the treatment of systemic rheumatic diseases.This arti-cle summarizes the progress of clinical application of CAR-T immunotherapy in systemic rheumatic dis-eases in recent years,aiming to enhance clinicians'cognition of CAR-T immunotherapy and promote the further development of CAR-T immunotherapy in systemic rheumatic diseases.
万方数据
维普
